Allorejection remains an obstacle for successful organ transplantation. Although different types of immunosuppressive agents are effective for controlling rejection and prolonging graft survival, drug treatment is limited because of side effects and toxicity. Therefore, it is necessary and urgent to identify new candidate drugs for inducing allotolerance. Recently, it has been reported that bacterial flagellin induces the immunosuppressive activity of regulatory T cells (Tregs) in humans in vitro. In the present study, we analyzed the effects of recombinant flagellin (rFliC) on allograft survival and explored the underlying mechanisms associated with the activation of recipient Tregs in a murine skin allotransplantation model. The results showed that rFliC administration (3 mg/kg, once per day for 3 days, i.p.) prolonged allograft survival (mean survival time: 18.461.1 days) compared to the control group (1060.7 days, P,0.01). Additionally, higher positive expression of Toll-like receptor 5 (TLR5) was detected within the allograft administered with rFliC. The frequency of CD4 1 CD25 1 Foxp3 1 Tregs; the expression of Treg-related factors TLR5, Foxp3, TGF-b1 and IL-10; and the proliferation and suppression of Tregs were increased following rFliC administration compared to the control. Moreover, the increased expression of tolerance-related molecules and the proliferation of Tregs induced by rFliC were attenuated by an anti-TLR5 blocking antibody both in vivo and in vitro. In conclusion, rFliC administration prolongs the survival of allografts, which is associated with the activation of recipient Tregs in a TLR5-dependent manner. rFliC may be a new candidate for anti-allorejection therapy.
INTRODUCTION
Allorejection significantly influences allograft survival. Therefore, minimizing the incidence and severity of allograft rejection remains a key goal in the clinic. Currently, the best approach to control rejection effectively remains unknown, although much effort has been expended to identify adequate control measures. Although different types of immunosuppressive agents are effective for controlling rejection and prolonging graft survival, drug treatment is limited because of side effects and toxicity. Therefore, it remains necessary and urgent to identify new candidate drugs for inducing allotolerance.
In recent years, the suppressive effects of CD4 6 Therefore, Foxp3 is considered a definitive lineage marker of nTregs.
Toll-like receptor 5 (TLR5) is a member of the MyD88-dependent TLR signaling family and functions as a pattern recognition receptor that recognizes pathogen-associated molecular patterns to trigger both innate and adaptive immunity. TLR5 has been reported to be expressed by numerous cell types, including monocytes, neutrophils, dendritic cells and T cells in humans, and it is preferentially expressed by mouse Tregs 7 but not B-cell subsets. 8 Bacterial flagellin is a specific ligand for TLR5, and the binding between TLR5 and flagellin leads to the activation of NF-kB and initiates an anti-microbial response. 9 The importance of TLR5 recognition has been demonstrated in both human and animal studies. 10, 11 Flagellin is the main component of Gram-negative bacterial flagella. 12 Over the past several years, a strong interest has emerged in developing flagellin as an adjuvant to stimulate immune responses. [13] [14] [15] [16] [17] Flagellin treatment has been shown to protect against chemical, bacterial and viral insults, and it has also exhibited radioprotective activity in mouse and primate models. [18] [19] [20] [21] In addition, studies have found that the coculture of human CD4
1 T cells with flagellin significantly increases their immunosuppressive capacity and increases the expression of Foxp3. 22, 23 Moreover, flagellin treatment in vitro was shown to enhance the suppressive capacity and expression of Foxp3 in human CD4
1 CD25 1 Tregs. 23 Furthermore, it was found that flagellin inhibited human neutrophil apoptosis. 24 Together, these data suggest that flagellin may serve as a promising new candidate for improving tolerance to allotransplantation through its effects on the immunosuppressive capacity of Tregs. Our previous study revealed that flagellin increased the upregulated expression of TLR5 and Foxp3 caused by rapamycin in vitro. 25 A recent study reported that the administration of a therapeutic dose of 100 mg flagellin/mouse was effective in increasing the number of donor-derived Tregs in chronic graftversus-host disease after bone marrow transplantation. 26 However, whether flagellin has an effect on allograft rejection in solid organ transplantation and whether flagellin increases the proportion and functions of recipient Tregs in flagellin-treated allotransplantation models remain unclear. Here, we show the effects of flagellin on allograft survival and explore downstream mechanisms associated with these effects in a skin allotransplantation model.
MATERIALS AND METHODS

Expression and purification of recombinant flagellin (rFliC)
The pGEX4T-2 plasmid containing GST-FliC-Burkholderia pseudomallei was a kind gift from Professor Ya-Lei Chen (Department of Biotechnology, National Kaoshiung Normal University, Taiwan, China). The FliC protein was expressed and purified as described previously. 27 Briefly, sequence-confirmed plasmids were transformed into BL21 Escherichia coli and induced with 1 mM IPTG. Then, recombinant FliC protein was extracted and purified from the supernatant of cell lysates using Glutathione Sepharose 4B (GalaxyBio, Beijing, China) according to the manufacturer's protocols. To remove any potential remaining trace levels of LPS, ToxinEraser endotoxin removal resin (Genscript Biotech, Piscataway, New Jersey, USA) was used. Purified protein was pooled and dialyzed against phosphate-buffered saline (PBS) at 4 uC for 24 h with frequent PBS changes. The purified protein was confirmed by SDS-PAGE and western blotting using an anti-GST Tag antibody (Ab) (Cw Biotechnology, Beijing, China) (See Supplementary Figure 1) . The purity of the extracted flagellin was .98%, and LPS contamination was ,0.1 EU/ml based on a limulus test. Purified rFliC was administered by intraperitoneal injection for the in vivo experiments and was directly added into the cultures for the in vitro experiments.
Animals
Wild-type (WT) female C57BL/6 (B6, H-2 b ) mice and BALB/c mice (H-2 d ) between 8 and 14 weeks of age were obtained from the Institute of Experimental Nuclear Medicine of Shandong University and the Experimental Animal Center of Shandong University. The mice were maintained under specific pathogen-free conditions in an air-conditioned room (temperature: 2461 uC) and fed sterilized laboratory food and water ad libitum. The mice were randomly grouped with at least five mice in each group. All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals under the approval of the Scientific Investigation Board of the Medical School of Shandong University (Jinan, China).
Establishment of the murine skin allotransplantation model
The murine skin allotransplantation model was established as previously reported. [28] [29] [30] Briefly, full thick skin grafts from donor C57BL/6 mice were transplanted onto the graft beds prepared on the backs of recipient BALB/c mice. Vaseline gauze and wound-plast were used and were removed on day 7 postgrafting. The skin allografts were then evaluated daily, and rejection was defined as necrosis of more than 90% of the graft. Each model group included at least five mice (figure 1).
Histology
Allograft sections were stained with hematoxylin and eosin for microscopic pathological evaluation. Immunohistochemical (IHC) staining was performed using SP-9002 HistostainTMPlus kits (ZSGB-BIO, Beijing, China) according to the manufacturer's protocols. Briefly, paraffin sections were pre-treated with xylene, ethanol, citric acid buffer and 3% H 2 O 2 and then blocked with 10% normal goat serum at room temperature for 20 min. For Foxp3 staining, the sections were additionally treated with 0.01% Triton X-100 (Solarbio, Beijing) for 10 min at room temperature. Next, the sections were incubated with either anti-TLR5 Ab (Biosynthesis Biotechnology, Beijing) or anti-Foxp3 Ab (ProteinTech Group, Chicago, Illinois, USA) at optimized concentrations at 4 uC for 12 h and the corresponding secondary Ab. The TLR5 and Foxp3 staining was visualized with the chromogen diaminobenzidine, and the sections were examined using an inverted biological microscope (DMIRB; Leica, Wetzlar, Hesse-Darmstadt, Germany) at a magnification of either 3100 or 3400, and the section were photographed.
Blocking experiments
For TLR5-blocking experiments in vivo, 200 mg per mouse anti-TLR5 Ab (Biosynthesis Biotechnology) was injected i.p. into the allografted models on day 21 of the transplantation operation, 1 h prior to the rFliC injection. For the in vitro blocking experiments, an anti-mTLR5 blocking antibody (Invivogen, San Diego, California, USA) was added to the culture at the beginning of the experiment for 1 h at 37 uC in a 5% CO 2 atmosphere. The specific blocking activity of the anti-TLR5 antibody on TLR5-dependent signaling was previously verified (data not shown).
Flow cytometry
Splenocytes and axillary lymph node cells from recipient mice were freshly prepared. Staining for the cell surface antigens CD4 and CD25 was performed prior to the intracellular staining for Foxp3 (all from eBioscience, San Diego, California, USA) according to the manufacturer's instructions. The samples were analyzed using a FACSCalibur flow cytometer (Becton, Dickinson & Co., Franklin Lakes, New Jersey, USA) and FlowJo software. The full gate strategy is presented in Figure 2 and is as follows: an initial lymphocyte gate was set based on the forward scatter and side scatter characteristics of the cells, and then a second gate for CD4 
Foxp3
1 cells were counted.
Cell preparation and sorting
Single-splenocyte suspensions were prepared as described previously. 31 Briefly, single spleen cell suspensions from WT or treated BALB/c mice were prepared, the red blood cells were lysed with RBC lysis buffer and the remaining cells were resuspended in complete RPMI medium (RPMI-1640 supplemented with 10% fetal bovine serum, 100 ng/ml penicillin and 100 U/ml streptomycin). The CD4 1 CD25 1 T cells and CD4 1 CD25 2 T cells (purity .98%) were sorted using magnetic-activated cell sorting technology (Miltenyi, BergischGladbach, Germany) according to standard protocols. The cells were resuspended in complete RPMI medium.
RT-PCR CD4
1 CD25 1 Tregs were lysed using Transzol reagent (TransGen Biotechnology, Beijing, China). The total RNA was extracted according to the manufacturer's instructions and the RNA reverse-transcribed using the EasyScript Two-
Step RT-PCR SuperMix kit (TransGen Biotechnology). Synthetic cDNA was amplified using 23TransTaq HiFi PCR SuperMixII (TransGen Biotechnology). To quantify the mRNA expression, the cDNA was subjected to real-time PCR on a thermocycler (IQ5 Real-Time PCR cycler; Bio-Rad, Hercules, California, USA) using the SYBR Green Reaction Kit (Takara Biotechnology (Dalian) Co., Dalian, Liaoning, China) according to the manufacturer's instructions with the following murine primers and GAPDH as an internal control: TLR5 forward 59-GCC ACA TCA TTT CCA CTC CT-39 and reverse 59-ACA GCC GAA GTT CCA AGA GA-39; Foxp3 forward 59-CCC AGG AAA GAC AGC AAC CTT-39 and reverse 59-TTC TCA CAA CCA GGC CAC TTG-39; TGF-b1 forward 59-TGA CGT CAC TGG AGT TGT ACGG-39 and reverse 59-GGT TCA TGT CAT GGA TGG TGC-39; IL-10 forward 59-GGT TGC CAA GCC TTA TCG GA-39 and reverse 59-ACC TGC TCC ACT GCC TTG CT-39; and GAPDH forward 59-TCA CCA CCA TGG AGA AGGC-39 and reverse 59-GCT AAG CAG TTG GTG GTG CA-39. The specificity of the RT-PCR was verified by analyzing the melting curves and agarose gel electrophoresis of the PCR amplification products. The relative expression of genes was analyzed using the 2 {DDC t method.
Western blotting
Freshly prepared CD4 
CD25
1 Tregs (Supplementary Figure 2c) were harvested and washed twice with cold PBS. The cell pellets were lysed on ice for 30 min in lysis buffer supplemented with a protease and phosphatase inhibitor mixture. The proteins were resolved via SDS-PAGE and western blotting was performed using the following antibodies: ant-TLR5 (Biosynthesis Biotechnology), antiFoxp3 (ProteinTech Group) and anti-b-actin (Sigma-Aldrich, St. Louis, Missouri, USA). H-TdR (PerkinElmer, Waltham, Massachusetts, USA) was then added to each culture for an additional 16 h. Cold PBS was added to stop the reaction and the cells were collected with a fiberglass membrane (Shanghai Xingya Purification Materials Corporation, Shanghai, China). After washing with cold PBS in triplicate and drying at 60 uC for 30 min, each of the fiberglass membranes was dipped into 2 ml scintillation solution and placed in the dark for 30 min. The radioactivity counts (dpm, decay per minute) were then detected using a SN-6930 Liquid Scintillation System (Hesuo Rihuan Photoelectric Instrument Co., Ltd, Shanghai, China). The data are presented as the mean6s.e.m. of triplicates representative of three independent experiments.
Cell proliferation assays
The culture medium used for these experiments consisted of RPMI 1640 supplemented with 10% fetal bovine serum, 100 ng/ ml penicillin and 100 U/ml streptomycin. For the proliferation assay in Figure 4a , purified Tregs (4310 4 per well) were cultured for 4 days at 37 uC in 5% CO 2 and 1 mCi 3 H-TdR was then added to each well for an additional 16 h. For the proliferation assays in Supplementary Figure 3a , freshly sorted Tregs (4310 4 per well) were pre-treated with anti-TLR5 blocking Ab for 1 h. Then, 4310 4 stimulator cells per well (antigen presenting cells, APCs), splenocytes from female WT-B6 mice pre-treated with 40 mg/ml mitomycin C for 40 min at 37 uC in 5% CO 2 ) or rFliC (0.1 mg/ml) or APCs1rFliC (0.1 mg/ml) were added to the culture for 4 days at 37 uC in 5% CO 2 . Next, 1 mCi 3 H-TdR was added to each well for an additional 16 h. Antibody control was established by pretreating the APCs with anti-TLR5 blocking Ab for 1 h prior to the addition of rFliC and Treg cells. The cells were then harvested and assayed as described above. The proliferation level was determined based on the radioactivity of the sample. The data are presented as either the mean6s.e.m. or fold change of triplicates pooled from three independent experiments. For the experiments in Figure 4b , the mice were euthanized on day 11 post-grafting, and CD4 
Suppression and mixed lymphocyte response (MLR) assays
series of Treg groups for 24-h cultures. Then, 3 H-TdR was added to each well and the subsequent steps were performed as described for the 3 H-TdR incorporation discussed above. For Supplementary Figure 3b, purified Tregs at 4310 4 per well were pre-treated with anti-TLR5 blocking Ab for 1 h and then cocultured with either APCs (4310 4 per well) or rFliC1APCs for 3 days. The rFliC and Ab was then washed off and Teffs (4310 4 per well) were added to the culture for the 24 h secondary MLR. Then, 1 mCi
Statistical analysis
Statistical analyses for the experiments except the quantitative RT-PCR were performed using Student's t-test, and the logrank test was used for the graft survival analysis. The data are presented as the mean values6s.e.m.. The C t values of the quantitative PCR experiments were statistically analyzed with Dunnet's post-test. P values ,0.05 were statistically significant.
RESULTS
Administration of rFliC prolongs skin allograft survival
Allotransplantation models were established as described in the section on 'Materials and methods'. As early as day 961.0 post-transplantation, acute rejection was observed in 9/10 skin grafts among PBS-injected hosts. This acute rejection was characterized by massive epidermal damage, scab formation and a rapid loss of graft volume. On day 1060.7 (n510), the skin grafts among the control mice were completely replaced by scar tissue (Figure 1b) . By contrast, 27 of 30 skin grafts administered to the rFliC-treated mice remained healthy until day 1461 (P,0.05). Gradual contraction was then observed. The skin grafts in the groups that were administered 3 mg/kg rFliC were completely rejected by day 18.461.1 (Figure 1a) . For further study, histological analyses were performed for all groups on day 11 post-transplantation. The results in Figure 1c show that the skin graft sections from the control mice stained with hematoxylin and eosin exhibit a clear border between the host and grafted skin, epidermal and dermal necrosis and extensive inflammatory cell infiltration. By contrast, the grafts from the 3 mg/kg rFliC-treated hosts showed healthy growth, which was manifest as an imprecise boundary between the host and grafted skin and less inflammation and skin appendage degeneration. Moreover, IHC staining was performed on both grafts, and high TLR5 expression was induced by rFliC treatment compared to the PBS control (Figure 1d ). Normal control and isotype controls (data not shown) were performed concurrently. The isotype control For c and d , the data are shown as the tendency for dispersion and were analyzed using the Mann-Whitney U test. P,0.05 indicates significance; *P,0.05. (e) IHC staining was performed for Foxp3 (in brown) on skin grafts from PBS control, rFliC-treated and TLR5-blocked mice on day 11. Representative graphs are shown (n56). IHC, immunohistochemical; Treg, regulatory T cell; TLR5, Toll-like receptor 5. 
Foxp3
1 cells in the total CD4 1 T-cell population was calculated. As shown in Figure 2c , the frequency of CD25
1
Foxp3
1 cells in the CD4 1 splenocytes from rFliCtreated recipients was significantly higher (15.25%61.6%) than the PBS controls (9.3%61.6%; P,0.05). The frequency of double-positive cells among the CD4 1 axillary lymph node cells was similarly increased in the rFliC-treated hosts (16.3%61.65%) compared to the PBS controls (10.8%60.93%; P,0.05) (Figure 2d ). These data indicate that the frequency of triplepositive cells in the rFliC-treated groups increased, which suggests that Tregs in rFliC-treated recipients may be activated and associated with the rFliC-induced anti-rejection function. These results provide a basis for further study of the functions of Tregs in rFliC-treated recipients.
To elucidate the signaling pathway in rFliC-induced regulation of recipient Tregs, we performed TLR5-blocking experiments in vivo as described above. Flow cytometric analysis was performed on isolated splenocytes and axillary lymph node cells from TLR5-blocked recipients to determine the proportion of CD4 1 CD25 1
1 Tregs. As shown in Figure 2a -d, the frequency of CD4
1 Tregs in the TLR5-blocked group was significantly decreased (10.95%61.05% in splenocytes, 12.1%60.98% in axillary lymph node cells; P,0.05) compared to the rFliC-treated group.
We also performed IHC staining for Foxp3 on the grafts of the PBS control, rFliC-treated and TLR5-blocked mice. As shown in Figure 2e , Foxp3 expression was significantly increased in the rFliC-treated group compared to the PBS control, but was clearly decreased in the TLR5-blocked recipients.
These data suggest that Tregs in rFliC-treated recipient mice may be activated in a TLR5-dependent manner and may be associated with the rFliC-induced anti-rejection function.
Expression of Treg-mediated immune tolerance-related molecules are increased in an allotransplantation model of mice treated with rFliC To determine whether the Tregs in the rFliC-treated recipients were activated, the expression of Treg-mediated immune tolerance-related molecules was analyzed. On the day that the grafts were fully rejected, Treg cells were prepared fresh from the splenocytes of the recipient. Quantitative RT-PCR assays were performed, and the results showed that the expression of TLR5, Foxp3, TGF-b1 and IL-10 were all increased in the rFliCtreated hosts compared to the controls, with fold mRNA increases of 3.3, 1.9, 8.4 and 2.9, respectively (P,0.05; Figure 3a) .
The increased expression of TLR5 and Foxp3 induced by rFliC was confirmed by western blotting (Figure 3b and c) . The data show that the TLR5 and Foxp3 proteins were increased in the rFliC-treated recipients compared to the controls (P,0.05).
To confirm whether this rFliC-induced activity was TLR5-dependent, the expression of Treg-mediated immune tolerancerelated molecules in TLR5-blocked recipients was determine. As shown in Figure 3 , the expression of TLR5, Foxp3, TGF-b1 and IL-10 were all significantly decreased in the TLR5-blocked mice compared to the rFliC-treated hosts (P,0.05).
These data suggest that the Tregs in rFliC-treated recipients were increased in number and were activated, which was associated with immunosuppression. Furthermore, it was demonstrated that the enhanced expression of these Treg-related molecules in the rFliC-treated recipients was induced in a TLR5-dependent manner.
Proliferative and suppressive function of rFliC-treated recipient CD4
1 CD25 1 Tregs is increased in a TLR5-dependent pathway To further test the function of the activated Tregs in rFliCtreated recipients and to investigate the role of the TLR5 signaling pathway in this activity, we analyzed the proliferation and suppression of Tregs in PBS control, rFliC-treated and TLR5-blocked groups of mice.
On the day that the grafts were fully rejected in the control group, three groups of Tregs were freshly prepared from splenocytes. The Tregs were the cultured and a 3 H-TdR incorporation assay was performed as described in the section on 'Materials and methods'. The results showed that the proliferation of Tregs in rFliC-treated recipients increased 96.4% (P,0.05) compared to the PBS control. The proliferation of TLR5-blocked recipients was decreased 43.5% (P,0.05) compared to the rFliC-treated group (Figure 4a) .
To determine the suppressive capacity of recipient Tregs, MLR assay was performed as described in the section on 'Materials and methods'. Figure 4b shows that the total proliferation (Treg1Teff) (dpm) in the rFliC-treated Tregs was 35.1%, 30.9% and 23.5% lower for the cells cocultured with Teffs from PBS control, rFliC-treated and naive non-grafted BALB/c mice, respectively, compared to the PBS-treated Tregs. Furthermore, the total proliferation in the TLR5-blocked Tregs cocultured with Teffs from PBS control, rFliC-treated and naive non-grafted BALB/c mice was 36.4%, 32.4% and 27.1% higher respectively, compared to the rFliC-treated Tregs (P,0.05). Collectively, these data suggest that Tregs exhibit increased functions in rFliCtreated allografted model mice, which is associated with the immunosuppressive effect elicited by rFliC administration. Furthermore, this rFliC-induced regulation of Treg function is TLR5-dependent.
In vitro Functions of CD4
1 CD25 1 Tregs induced by rFliC are TLR5-dependent To further confirm the functions of the Tregs induced by rFliC and the role of TLR5 signaling, Tregs treated with rFliC were examined in vitro with an anti-TLR5 blocking antibody. The results are presented in Supplementary Figures 2 and 3 . These data indicate that the Treg activities were significantly upregulated by rFliC treatment in vitro, which is consistent with our previous data. More importantly, these results indicate a key role for TLR5 signaling in these rFliC-induced effects.
DISCUSSION
Although different types of effective immunosuppressive agents have been used post organ transplantation in the clinic, the severe adverse effects of these agents remain an obstacle to therapy. Therefore, it is necessary to identify new candidate drugs that induce allograft tolerance. In this study, we found that the survival of allografts was significantly improved following the administration of rFliC. This effect of rFliC was not strain-specific because the experiments were repeated in established B6RBALB/c models, and the results were consistent with this study.
The anti-rejection effect of rFliC may be caused by a comprehensive mechanism in addition to the activation of recipients Treg, which may be a mix of antigen-specific Tregs and nonspecific Tregs. Moreover, because the histological analysis confirmed the reduced inflammation caused by rFliC administration and because it was reported that rFliC induced the reduction of graft-versus-host disease by decreasing pro-inflammatory 2 Teffs were isolated on the day that the control grafts were completely rejected. (a) The dpms representing the proliferation of Tregs from PBS control, rFliC-treated and TLR5-blocked recipients were measured. (b) MLR assays were performed using purified Tregs and Teffs from rFliC-/PBS-treated and TLR5-blocked recipients and naive mice. The results are presented as the total counts (dpm) of the MLR culture as measured by 3 H-TdR incorporation. Student's t-test was used for statistical analysis, and P,0.05 indicates significance. dpm, decay per minute; MLR, mixed lymphocyte response; PBS, phosphate-buffered saline; rFliC, recombinant flagellin; Treg, regulatory T cell; TLR5, Toll-like receptor 5.
cytokines produced by donor T cells, 26 it was hypothesized that rFliC administration may change the inflammatory markers and cytokines of recipients. These issues must be extensively explored in future studies.
Our data indicate that rFliC administration augments expression of the CD4 Tregs further confirmed that the Tregs in the rFliC-treated hosts increased. The MLR-3 H-TdR incorporation strategy was referenced from previous publications, [32] [33] [34] which was useful for evaluating lymphocyte function, particularly the inhibition of proliferation.
In our present study, a dose of 3 mg/kg flagellin was used. However, further research is necessary to determine whether effect of flagellin is dose-dependent. Moreover, despite its observed beneficial effects on immune tolerance, the potential adverse effects of flagellin were not evaluated in our study, and a careful assessment of the potential risks is essential.
The in vivo and in vitro experiments on the sorted Tregs further support our hypothesis. Interestingly, the anti-TLR5 blocking antibody blocked the activation and induction of CD4 1 CD25 1 Tregs. The anti-TLR5 antibody we used was shown to be specific in our previous study. In addition, flagellin is the specific ligand of TLR5. The data indicate that TLR5 signaling is responsible for the observed effects. The purpose of the antibody control was to prove the specificity of the anti-TLR5 antibody. Proliferation of the Treg cells cocultured with antibody-treated APCs was not significantly different from the Treg cells cocultured with untreated APCs, but the proliferation of Treg cells pre-treated with the anti-TLR5 antibody was significantly decreased. Therefore, the unspecific neutralization of antibody could be excluded, and the results of the blocking experiment were due to the anti-TLR5 antibody.
We found that for the rFliC-treated recipient Tregs, the mRNA and protein expression of Foxp3 was increased, and the frequency of the CD4 1 CD25 1 Foxp3 1 cell subset increased. Moreover, these rFliC-induced actions were attenuated by TLR5 blockage in vivo. Identification of the specific signaling mechanism of increased Foxp3 expression in recipient Tregs after rFliC administration must be performed.
Collectively, our results demonstrate that allograft survival is prolonged by flagellin administration. For the mechanisms associated with TLR5 activation, rFliC increased Foxp3 expression and increased the proportion of Tregs. The functions of recipient Tregs were increased by rFliC treatment in vivo, which was associated with TLR5 signaling. Because the protective and adjuvant effects of rFLiC have been reported, rFliC may be considered for allotolerance inducing therapy.
This report provides insight for the development of anti-allorejection drugs in solid organ allotransplantation.
